Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28132102)

Published in Rheumatol Int on January 28, 2017

Authors

Yoon-Kyoung Sung¹^,2, Soo-Kyung Cho¹^,2, Dam Kim¹^,2, Chan-Bum Choi¹^,2, Soyoung Won², So-Young Bang³, Hoon-Suk Cha⁴, Jung-Yoon Choe⁵, Won Tae Chung⁶, Seung-Jae Hong⁷, Jae-Bum Jun¹, Hyoun Ah Kim⁸, Jinseok Kim⁹, Seong-Kyu Kim⁵, Tae-Hwan Kim¹, Hye-Soon Lee³, Jaejoon Lee⁴, Jisoo Lee¹⁰, Shin-Seok Lee¹¹, Sung Won Lee⁶, Yeon-Ah Lee⁷, Seong-Su Nah¹², Chang-Hee Suh⁸, Dae-Hyun Yoo¹, Bo Young Yoon¹³, Sang Cheol Bae¹⁴^,15, BIOPSY and KORONA investigators

Author Affiliations

1: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea.
2: Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea.
3: Guri Hospital, Hanyang University, Guri, South Korea.
4: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
5: School of Medicine, Catholic University of Daegu, Daegu, South Korea.
6: Dong-A University Hospital, Busan, South Korea.
7: Kyung Hee University Hospital, Seoul, South Korea.
8: Ajou University Hospital, Suwon, South Korea.
9: Jeju National University Hospital, Jeju, South Korea.
10: Ewha Womans University Mokdong Hospital, Seoul, South Korea.
11: Chonnam National University Medical School and Hospital, Gwangju, South Korea.
12: Soonchunhyang University Cheonan Hospital, Cheonan, South Korea.
13: Inje University Ilsan Paik Hospital, Goyang, South Korea.
14: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea. scbae@hanyang.ac.kr.
15: Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea. scbae@hanyang.ac.kr.

Articles cited by this ↗

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med (2007) 5.05

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98

Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med (2013) 3.51

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum (2010) 3.31

State-of-the-art: rheumatoid arthritis. Ann Rheum Dis (2010) 2.06

Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum (2013) 1.72

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis (2012) 1.64

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.61

Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis (2004) 1.47

Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum (2008) 1.24

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis (2013) 1.11

The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum (2006) 1.08

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. Arthritis Rheum (2009) 1.04

Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum (2011) 1.02

The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol (2009) 0.94

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum (2013) 0.93

Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) (2002) 0.87

Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken) (2014) 0.84

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One (2015) 0.80

Articles by these authors ⇆

Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum (2017) 0.75

Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Semin Arthritis Rheum (2017) 0.75

Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatol Int (2017) 0.75